They reported significant improvement in mean fasting serum insulin (pre-RFA 39.4 ± 8.9 vs. post-RFA 13.1 ± 5.1; p < 0.001) and fasting blood glucose (pre-RFA 30.3 ± 7.3 vs. post-RFA 78.2 ± 7.7; p < 0.001) after a median follow-up of 31.5 months, and clinical response was seen in all the cases with insulinomas. The gene discussed is INS; the disease is pancreatic insulinoma.